Hikma stock heads into the open after a modest FTSE 100 gain

At the close on September 18, 2026, Hikma stock finished the London session little changed while the FTSE 100 added modestly on the day. Recent attention has centered on a recall of blood-pressure medication linked to Hikma Pharmaceuticals, noted by US regulators.

At the close on September 18, 2026, Hikma stock ended the London Stock Exchange session almost flat, with a slight move that lagged a modest gain in the FTSE 100 on the same day. The broader index advanced by a small single-digit percent move, underscoring that Hikma's share price saw only limited direction compared with the wider market.

September 18, 2026 in numbers

Hikma Pharmaceuticals plc (ISIN GB00B128J450) closed on September 18, 2026 on its primary London listing with a marginal percentage change versus the prior close, reflecting a relatively calm trading day for the stock. The intraday range between the day's high and low remained tight, and trading volume stayed within normal levels for recent weeks, indicating neither pronounced buying interest nor significant selling pressure. The close fitted comfortably within Hikma's 52-week range, showing that the stock did not test either recent highs or lows during the session.

Against this backdrop, the FTSE 100 benchmark posted a small gain on September 18, 2026, so Hikma's flat performance slightly underperformed the index's advance. Market data for United Kingdom large caps showed that some peers in the healthcare and pharmaceuticals space participated more clearly in the index's upward move, while Hikma's shares held broadly steady. This quantified comparison between Hikma and the FTSE 100 on September 18, 2026 highlights that the stock's latest session was characterized more by consolidation than by a decisive move in either direction.

Regulatory focus and today's backdrop

Regulatory headlines have kept Hikma in focus in recent days, as authorities in the United States highlighted a recall of bottles of blood-pressure medication associated with Hikma Pharmaceuticals and manufacturing partners. As NTD reported on September 20, 2026, Hikma Pharmaceuticals initiated a recall of a lot of blood-pressure drug packaged by West-Ward Columbus Inc. for Exelan Pharmaceuticals following notification from the Food and Drug Administration, which may keep regulatory and safety questions in view for investors. Today, Hikma stock heads into the open with this recent recall context still fresh, and traders can also reference the latest move in the FTSE 100 and broader pharmaceuticals sector as they assess the stock's risk and sentiment profile.